March 20, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer

Basel, 20 March 2018 Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met its... Read more

March 16, 2018 Bio/Pharma/CRO Clinical Research/Diagn. Lab Top-10

Thermo Fisher Scientific Announces Plans to Build State-of-the-Art Pharma Services Facility in Rheinfelden (Baden) Germany

Thermo Fisher Scientific Announces Plans to Build State-of-the-Art Pharma Services Facility in Rheinfelden (Baden) Germany New site will support complex clinical research and bring more than 200 new jobs to community RHEINFELDEN, Germany, March 16, 2018 /PRNewswire/ — Thermo Fisher Scientific announced today it is expanding its footprint in the European Union and investing $35 million... Read more

March 5, 2018 Bio/Pharma/CRO Lab Top-10 M&A, Partnerships

MilliporeSigma and Schneider Electric Sign MoU to Advance China’s Biopharmaceutical Industry

MilliporeSigma and Schneider Electric combine capabilities to automate biopharmaceutical process Customers would save time, get greater flexibility with automated solution Shanghai, China, March 5, 2018 — MilliporeSigma, a leading science and technology company, and Schneider Electric, a global specialist in energy management and automation, announced the signing of a Memorandum of Understanding (MoU) that aims to automate... Read more

February 20, 2018 Bio/Pharma/CRO PR/Corporate

GE Healthcare Named to Fast Company’s Top 10 Most Innovative Companies in Biotech for Putting Patients in Control of their Mammograms

CHICAGO – February 20, 2018 – GE Healthcare announced today its being recognized as one of Fast Company’s Most Innovative Companies of 2018. As a leading maker of medical diagnostic equipment, GE Healthcare was honored on the Top 10 Most Innovative Companies in Biotech list for the launch of its latest mammography system, Senographe Pristina.... Read more

February 20, 2018 Bio/Pharma/CRO PR/Corporate

GE Healthcare Named to Fast Company’s Top 10 Most Innovative Companies in Biotech for Putting Patients in Control of their Mammograms

CHICAGO – February 20, 2018 – GE Healthcare announced today its being recognized as one of Fast Company’s Most Innovative Companies of 2018. As a leading maker of medical diagnostic equipment, GE Healthcare was honored on the Top 10 Most Innovative Companies in Biotech list for the launch of its https://www.genewsroom.com/press-releases/ge-healthcare-named-fast-companys-top-10-most-innovative-companies-biotech-putting Read more

February 12, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema

Basel, 12 February 2018 Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema RG7716 is the first bispecific antibody designed specifically for the treatment of retinal eye diseases RG7716 demonstrated clinically meaningful and statistically significant improvements in visual acuity Key secondary and exploratory anatomical outcomes were... Read more

February 6, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more

February 6, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more

February 6, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more

February 6, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more